| In recent years, because of the rapid economic development of the world and the environment deteriorating, the incidence of malignant tumor has increased year by year, though medical level gradually developed, in most malignant tumor still can't be cured. The treatment of malignant tumor methods are: (1) surgery (2) chemotherapy (3) radiotherapy (4) biological immune therapy (5) comprehensive treatment. And immunotherapy has become an important auxiliary treatment of malignant tumors, following surgery, radiotherapy and chemotherapy. With the rapid development of cytobiology, immunotherapy has improved and perfected, meanwhile the therapeutic effect of malignant tumors and the quality of survival in patients improved greatly, but also extending the disease-free survival.Adoptive cellular immunotherapy(ACI)is a treatment to damage the tumor cells by inject the immune cells, which can mediate the anti-tumor effect directly or indirectly through autogenous or allograft by in vitro culture, amplification, activation. CIK cells and DC cells are two important currently immune cells in the immune therapy, DC can identify the pathogens and activate acquired immune system, CIK display its own cell toxicity and secrete some cytokines to kill the tumor cells, the combination of these two cells ensure immune response completed efficiently and harmoniously. Therefore, these two cells(DCCIK) co-culture and alliance application will become the key of Adoptive immune therapy. At present, the treatments has a certain clinical curative effect in many kinds of tumors such as breathing, digestion, urinary, blood and reproductive.Objective:This paper analyzed the cell biology characteristics and function mechanism of DC and CIK and the cancer treatment in different system, also discussed the results of gastrointestinal system tumors after treatment of patients in biological treatment center of our hospital, such as immune function, quality of life etc. Discussed the treatment effect of digestive system cancer in middle-late patients of Adoptive immune therapy (DC united CIK cells), observed the improvement of immune function of patients before and after treatment, and made the assessment of short-term curative effect, thus provided the clinical application material and evidence that the Adoptive cellular immunotherapy can be used as common clinical treatments in middle-late digestive system tumor.Methods:We collected and sorted the patients of biological therapy center in our hospital from June 2010 to January 2011. 58 cases with middle-late digestive system tumor (male 33, female 25, median age 61) received DC united CIK cell therapy, analyzed the changes of the immune indexes and the general condition before and after treatment.Results: After the mononuclear cell of those 58 patients cultured 10 days in vitro, CD3 + cell count grew by an average of 40 times; The percentage of CD3 + / CD56 + cells grew from 3.1% to 29.60%, cell count amplified by an average of 330 times. Therefore the expansion method in vitro of this research has a high performance of amplify the CIK cells and display a powerful anti-tumor effect. CD3+,CD3+ /CD4+ positive cells of the 58 patients increased significantly after 7 days treatment of DC-CIK cells, and CD3 + / CD8 + cells dropped, significant difference (P < 0. 05), which proved that this treatment can significantly strengthen the body cellular immune ability, thus make the body anti-tumor immune effect gets significantly improvement. Febricity occasionally happened during the treatment, with an incidence of 17%. After the treatment, about 70 % of the patients'Casette score increased about 15 points on average, it is related with the immune function improvement. The quality life of 68.3% patients gets improvement, performance for physical certain strengthening, appetite, pain mitigated, sleep better improvement, etc. In clinical curative effect of treating cancer the tumors control rate was 77.6%, the total effective rate was 56.9%. This study found that different parts of the digestive system have different curative effect, colorectal cancer and pancreatic cancer have a higher efficacy, while the lowest in hepatocellular carcinoma.Conclusion:1.This study adopts mononuclear cells by acquisition machine, ensuring more mononuclear cells can be collected; Using patient's own pyrolysis tumor cells(or tumor cell line) as DC allergoid in order to guarantee the strong specificity of destruct the tumor cells; In this study, NKT cells proportion reachs more than 30%, and CIK cell becomes more and reachs more than 1x 10~9, a greater degree of tumor cells to strengthen the destruction. 2. DC-CIK cellular immune therapy can improve immune function of the middle-late digestive system tumors and display a powerful anti-tumor immune effect, which is a safety and effective antitumor therapy. 3. DC-CIK cellular immune therapy can improve the patient's immune status and anti-tumor capacity and the quality life of the patients. 4. DC-CIK cellular immune therapy provides new ideas and means for carcinoma and diseases of immune abnormalities, with excellent application prospects.
|
PDF Full Text Request